An ISO 9001-2008 Certified Company | GSTIN : 03AACCJ9011H1ZY  | Drug Licence No.: 20B 130016,21B 130017  |   Email : infojabsbiotech@gmail.com, jabsbiotech@gmail.com | Any Query : 9888761706 | For Accounts : 9855661706 | For Sales : 7696761706 | For Dispatch : 7973383341

+917973383341 +9198887 61706 Jabsbiotech@gmail.com Product Visual Aid
  • 0Shopping Cart
  • Home
  • About Us
  • Our Products
    • Tablets
    • Capsules
    • Injections
    • SYRUP
    • Powder/Sachets/Ear Drop/Nasal Spray
  • PCD Franchise
  • Divisions
    • Corium
    • Next Life Sciences
    • Jabs Ayurveda
    • Alostar Pharma
  • Contact Us
  • Blog
  • TrackUrShipment
  • Search
  • Menu
You are here: Home / TABLETS / ELMY-40

Target Area For PCD Franchise

  • PCD Pharma Franchise Arunachal Pradesh
  • Pharma Franchsie in Assam
  • PCD Franchise in Manipur
  • Pharma Franchise in Meghalaya
  • PCD Pharma Franchise in Mizoram
  • Pharma Franchise in Nagaland
  • PCD Pharma Franchise in Sikkim
  • Pharma PCD Franchise in Tripura
  • Pharma Franchise in Goa

ELMY-40

₹64.00

TELMISARTAN-40MG.(ALU-ALU)

SKU: 79436cb88f50 Category: TABLETS
  • Description
  • Additional information

Description

Telmisartan belongs to a class of medications known as angiotensin II receptor antagonists. These medications reduce blood pressure by blocking the actions of a chemical (angiotensin II) that causes blood vessels to constrict or tighten. It is used to treat mild to moderate high blood pressure.When blood pressure is allowed to remain high for a long time, the blood vessels of the heart, kidneys, and brain may become damaged. This puts a person at increased risk for heart attack and stroke as well as kidney failure and blindness. Keeping blood pressure in the normal range can reduce the risk for these conditions.Telmisartan is also used to reduce the risk of death after a heart attack in people who cannot use another type of medication called angiotensin-converting enzyme inhibitor.

DOSEAGE:

The usually effective dose is 40 mg once daily.

INDICATIONS

• Hypertension

• Coronary heart disease

• Stroke

• Peripheral arterial disease

SIDE EFFECTS

• Changes in vision

• Dizziness, lightheadedness, or fainting

• Fast heartbeat

• Large hives

• Painful urination or changes in urinary frequency

• Swelling in the hands, lower legs, and feet

DRUG INTERACTIONS

Digoxin

When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. When initiating, adjusting, and discontinuing telmisartan, monitor digoxin levels in order to maintain levels within the therapeutic range.

As with other medicinal products acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia. The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products, heparin, immunosuppressives, and trimethoprim.

Potassium sparing diuretics or potassium supplements

Angiotensin II receptor antagonists such as telmisartan attenuate diuretic induced potassium loss. Potassium sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or potassium-containing salt substitutes may lead to a significant increase in serum potassium. If concomitant use is indicated because of documented hypokalaemia, they should be used with caution and with frequent monitoring of serum potassium.

Lithium

Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor antagonists, including telmisartan. If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.

Non-steroidal anti-inflammatory medicinal products

NSAIDs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and nonselective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists.

In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.

Corticosteroids

Reduction of the antihypertensive effect.

Additional information

Packsize

10*10

Related products

  • ETIJAB-0.25

    ₹30.00
    Add to cart Show Details
  • EMPIA-40

    ₹75.00
    Add to cart Show Details
  • DOXIJAB-O

    ₹250.00
    Add to cart Show Details
  • CEFIJAB-O

    ₹190.00
    Add to cart Show Details

Jabs Biotech PVT LTD is researching and making medicine which is accessible to all by.

Contact Us

    Short Links
    • Home
    • About Us
    • PCD Franchise
    • Contact Us
    • Privacy Policy
    Follow Us
    Jabs Biotech Pvt. Ltd.

    Regd.Office:-
    Sangatpura ST.No. 5, Near Patiala Gate,Nabha(Punjab)

    Mkt. Office:-
    W/5 New Friends Colony,
    Near Delhi –Alwar Highway,
    Sohna(Gurgaon)

    Email Id:- Jabsbiotech@gmail.com
    Mobile No:- +917973383341, +91 98887-61706 +91 99146-45693
    Landline No:- 01765-505706

    © Jabs Biotech Pvt Ltd | Web Design & Development By WebHopers
    • Home
    • About Us
    • PCD Franchise
    • Contact Us
    • Privacy Policy
    PLACE A QUERY

      Call Us Contact Us
      ×

        ELMY-TRIO Scroll to top